Malignancy and Meckel’s diverticulum: A systematic literature review and 14-year experience at a tertiary referral center

Kathleen van Malderen, Priya Vijayvargiya, Michael Camilleri, David Larson, Robert Cima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Meckel’s diverticulum is present in about 2% of the population. The literature reports 3.2% incidence of tumors within Meckel’s diverticulum; the tumors are predominantly benign. Objective and methods: The purpose of this study was to evaluate malignant tumors in Meckel’s diverticulum through systematic review of the literature and review of electronic medical records including pathology reports over 14 years at the Mayo Clinic, Rochester, USA. Results: A literature review over the last 10 years identified 37 citations with 402 patients (median age: 58 years; 68.9% males). The predominant malignancy reported was neuroendocrine tumor 84.6%, followed by gastrointestinal stromal tumor 8.2%, and adenocarcinoma 6%. At the time of diagnosis, 29.5% of patients had metastases. In the Mayo Clinic electronic medical records review, there were 19 patients (5.1% of them surgically removed Meckel’s diverticulum) who had a malignancy associated with Meckel’s diverticulum: 63.2% neuroendocrine tumor, 10.5% gastrointestinal stromal tumor, 5.3% adenocarcinoma, 5.3% pancreatic epithelial neoplasia, and 15.8% metastases from secondary location. Median size of the malignancy was 7 mm, and 17/19 malignancies were coincidental findings. Most neuroendocrine tumors infiltrated the submucosa, while gastrointestinal stromal tumor and adenocarcinoma invaded the serosa. At the time of diagnosis, 33.3% of patients had metastases. Conclusion: About 5% of Meckel’s diverticulums resected were associated with malignant tumors, most commonly neuroendocrine tumor, and a significant portion of Meckel’s diverticulum malignancy was metastatic at the time of discovery.

Original languageEnglish (US)
Pages (from-to)739-747
Number of pages9
JournalUnited European Gastroenterology Journal
Volume6
Issue number5
DOIs
StatePublished - Jun 1 2018

Fingerprint

Meckel Diverticulum
Tertiary Care Centers
Neuroendocrine Tumors
Neoplasms
Gastrointestinal Stromal Tumors
Adenocarcinoma
Electronic Health Records
Neoplasm Metastasis
Serous Membrane
Pathology

Keywords

  • adenocarcinoma
  • Carcinoid
  • gastrointestinal stromal tumor
  • neuroendocrine tumor

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Malignancy and Meckel’s diverticulum : A systematic literature review and 14-year experience at a tertiary referral center. / van Malderen, Kathleen; Vijayvargiya, Priya; Camilleri, Michael; Larson, David; Cima, Robert.

In: United European Gastroenterology Journal, Vol. 6, No. 5, 01.06.2018, p. 739-747.

Research output: Contribution to journalArticle

@article{ab6a9330f6a645979b379d0d4176d7ed,
title = "Malignancy and Meckel’s diverticulum: A systematic literature review and 14-year experience at a tertiary referral center",
abstract = "Background: Meckel’s diverticulum is present in about 2{\%} of the population. The literature reports 3.2{\%} incidence of tumors within Meckel’s diverticulum; the tumors are predominantly benign. Objective and methods: The purpose of this study was to evaluate malignant tumors in Meckel’s diverticulum through systematic review of the literature and review of electronic medical records including pathology reports over 14 years at the Mayo Clinic, Rochester, USA. Results: A literature review over the last 10 years identified 37 citations with 402 patients (median age: 58 years; 68.9{\%} males). The predominant malignancy reported was neuroendocrine tumor 84.6{\%}, followed by gastrointestinal stromal tumor 8.2{\%}, and adenocarcinoma 6{\%}. At the time of diagnosis, 29.5{\%} of patients had metastases. In the Mayo Clinic electronic medical records review, there were 19 patients (5.1{\%} of them surgically removed Meckel’s diverticulum) who had a malignancy associated with Meckel’s diverticulum: 63.2{\%} neuroendocrine tumor, 10.5{\%} gastrointestinal stromal tumor, 5.3{\%} adenocarcinoma, 5.3{\%} pancreatic epithelial neoplasia, and 15.8{\%} metastases from secondary location. Median size of the malignancy was 7 mm, and 17/19 malignancies were coincidental findings. Most neuroendocrine tumors infiltrated the submucosa, while gastrointestinal stromal tumor and adenocarcinoma invaded the serosa. At the time of diagnosis, 33.3{\%} of patients had metastases. Conclusion: About 5{\%} of Meckel’s diverticulums resected were associated with malignant tumors, most commonly neuroendocrine tumor, and a significant portion of Meckel’s diverticulum malignancy was metastatic at the time of discovery.",
keywords = "adenocarcinoma, Carcinoid, gastrointestinal stromal tumor, neuroendocrine tumor",
author = "{van Malderen}, Kathleen and Priya Vijayvargiya and Michael Camilleri and David Larson and Robert Cima",
year = "2018",
month = "6",
day = "1",
doi = "10.1177/2050640617752771",
language = "English (US)",
volume = "6",
pages = "739--747",
journal = "United European Gastroenterology Journal",
issn = "2050-6406",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Malignancy and Meckel’s diverticulum

T2 - A systematic literature review and 14-year experience at a tertiary referral center

AU - van Malderen, Kathleen

AU - Vijayvargiya, Priya

AU - Camilleri, Michael

AU - Larson, David

AU - Cima, Robert

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Meckel’s diverticulum is present in about 2% of the population. The literature reports 3.2% incidence of tumors within Meckel’s diverticulum; the tumors are predominantly benign. Objective and methods: The purpose of this study was to evaluate malignant tumors in Meckel’s diverticulum through systematic review of the literature and review of electronic medical records including pathology reports over 14 years at the Mayo Clinic, Rochester, USA. Results: A literature review over the last 10 years identified 37 citations with 402 patients (median age: 58 years; 68.9% males). The predominant malignancy reported was neuroendocrine tumor 84.6%, followed by gastrointestinal stromal tumor 8.2%, and adenocarcinoma 6%. At the time of diagnosis, 29.5% of patients had metastases. In the Mayo Clinic electronic medical records review, there were 19 patients (5.1% of them surgically removed Meckel’s diverticulum) who had a malignancy associated with Meckel’s diverticulum: 63.2% neuroendocrine tumor, 10.5% gastrointestinal stromal tumor, 5.3% adenocarcinoma, 5.3% pancreatic epithelial neoplasia, and 15.8% metastases from secondary location. Median size of the malignancy was 7 mm, and 17/19 malignancies were coincidental findings. Most neuroendocrine tumors infiltrated the submucosa, while gastrointestinal stromal tumor and adenocarcinoma invaded the serosa. At the time of diagnosis, 33.3% of patients had metastases. Conclusion: About 5% of Meckel’s diverticulums resected were associated with malignant tumors, most commonly neuroendocrine tumor, and a significant portion of Meckel’s diverticulum malignancy was metastatic at the time of discovery.

AB - Background: Meckel’s diverticulum is present in about 2% of the population. The literature reports 3.2% incidence of tumors within Meckel’s diverticulum; the tumors are predominantly benign. Objective and methods: The purpose of this study was to evaluate malignant tumors in Meckel’s diverticulum through systematic review of the literature and review of electronic medical records including pathology reports over 14 years at the Mayo Clinic, Rochester, USA. Results: A literature review over the last 10 years identified 37 citations with 402 patients (median age: 58 years; 68.9% males). The predominant malignancy reported was neuroendocrine tumor 84.6%, followed by gastrointestinal stromal tumor 8.2%, and adenocarcinoma 6%. At the time of diagnosis, 29.5% of patients had metastases. In the Mayo Clinic electronic medical records review, there were 19 patients (5.1% of them surgically removed Meckel’s diverticulum) who had a malignancy associated with Meckel’s diverticulum: 63.2% neuroendocrine tumor, 10.5% gastrointestinal stromal tumor, 5.3% adenocarcinoma, 5.3% pancreatic epithelial neoplasia, and 15.8% metastases from secondary location. Median size of the malignancy was 7 mm, and 17/19 malignancies were coincidental findings. Most neuroendocrine tumors infiltrated the submucosa, while gastrointestinal stromal tumor and adenocarcinoma invaded the serosa. At the time of diagnosis, 33.3% of patients had metastases. Conclusion: About 5% of Meckel’s diverticulums resected were associated with malignant tumors, most commonly neuroendocrine tumor, and a significant portion of Meckel’s diverticulum malignancy was metastatic at the time of discovery.

KW - adenocarcinoma

KW - Carcinoid

KW - gastrointestinal stromal tumor

KW - neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=85048338575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048338575&partnerID=8YFLogxK

U2 - 10.1177/2050640617752771

DO - 10.1177/2050640617752771

M3 - Article

AN - SCOPUS:85048338575

VL - 6

SP - 739

EP - 747

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 5

ER -